Orion has entered into an R&D collaboration agreement with DelSiTech Ltd, Turku, Finland. The agreement allows Orion to apply the unique and proprietary DelSiTech® drug delivery technology in its drug development projects for different therapeutic purposes. The agreement also provides Orion with an option for licensing and further collaboration.

The DelSiTech drug delivery technology is a result of a cross-disciplinary project including top researchers from the University of Turku and Åbo Akademi, the Swedish-speaking University in Turku. The Biomaterial Research Group includes dentists, physicians, chemists, engineers and pharmacists and is globally one of the largest of its kind in the research of bioactive glass, sol-gel and glass fiber reinforced materials mainly for dental, orthopedic and drug delivery applications.